Overexpression of human epidermal growth factor receptor 2 allows theranostic targeting with the monoclonal antibody trastuzumab (51,74) in cancers of the breast, ovary, endometrium, bladder, lung, and gastrointestinal tract (51) using DOTA chelation of 64Cu, 89Zr, 68Ga and 177Lu (75). Here, ERBB2 is linked to cancer.